Clovis Oncology   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Boulder CO United States (2009)

Organization Overview

First Clinical Trial
2010
NCT01009190
First Marketed Drug
2016
rucaparib (rubraca)
First NDA Approval
2016
rucaparib (rubraca)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Clovis Oncology | Clovis Oncology, Inc. | CLOVIS ONCOLOGY INC

Indications

Approved Indications


 

Ovarian Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma, Clear Cell (Phase 3)

Adenomyoepithelioma (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Endometrioid (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Carcinosarcoma (Phase 2)

Cystadenocarcinoma, Serous (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Hypersensitivity (Phase 2)

Leiomyosarcoma (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 3)

Mesothelioma (Phase 2)

Mixed Tumor, Mullerian (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 57
  • # of Trial APIs: 38